Headlines about Exactech (NASDAQ:EXAC) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Exactech earned a news impact score of 0.08 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.5342758995592 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s analysis:
- Exactech (EXAC) Cut to Hold at ValuEngine (americanbankingnews.com)
- Growing Geriatric Population To Drive U.S. Knee Implants Market Expected To Worth US$7.0 Billion by 2024 (menafn.com)
- Spinal Fusion Devices Market foreseen to grow exponentially at 4.65% CAGR over 2017 – 2025 (dcvelocity.com)
- Artificial Implants Market to Be at Forefront by 2019 (sbwire.com)
- Paul J. Burkhart Welcomes Maxwell Christiansen to Palm Beach Gardens Law Firm (newswire.net)
Several research analysts recently weighed in on EXAC shares. ValuEngine downgraded Exactech from a “buy” rating to a “hold” rating in a research note on Friday. Gabelli cut Exactech from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Zacks Investment Research cut Exactech from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Robert W. Baird set a $34.00 price objective on Exactech and gave the company a “buy” rating in a report on Sunday, October 15th. Finally, Sidoti cut Exactech from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $42.00.
Exactech (NASDAQ:EXAC) last posted its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). The company had revenue of $61.40 million during the quarter, compared to analysts’ expectations of $61.78 million. Exactech had a net margin of 0.18% and a return on equity of 7.22%. equities analysts anticipate that Exactech will post 1.29 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Exactech (EXAC) Receives News Impact Score of 0.08” was first reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/04/exactech-exac-receiving-somewhat-positive-news-coverage-report-shows.html.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.